The effects of moclobemide on the yohimbine-induced anxiogenic action in the elevated plus-maze

Pharmacological Research

Volumn 37, Issue 2, 1998, Pages 137-143

  Eroglu L ^a   Guven O ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Anxiolytic action; Moclobemide; Plus maze; Yohimbine

Indexed keywords

ANXIOLYTIC AGENT; MOCLOBEMIDE; NORADRENALIN; YOHIMBINE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FORCED SWIMMING TEST; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT;

EID: 0032005159     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0275     Document Type: Article

References (43)

1. 1. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman Goodman A, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw Hill, 1996: pp. 431-59.
2. 2. Rudorfer MV. Monoamine oxidase inhibitors: reversible and irreversible. Psychopharmacol Bull 1992; 28: 45-57.
3. 3. Tipton KF. Enzymology of monoamine oxidase. Cell Biochem Func 1986; 4: 79-87.
4. 4. Yang HYT, Neff NH. The monoamine oxidase of brain. Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 1974; 189: 733-40.
5. 5. Lipper S, Murphy DL, Slater S, Buchsbaum MS. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology 1979; 62: 123-8.
6. 6. Murphy DL, Lipper S, Campbell K, Major LF, Slater S, Buchsbaum MS. Comparative studies of MAO-A and MAO-B inhibitors in man. In: Singer TP, Von Kort RW, Murphy DL, eds. Monoamine Oxidase, Structure, Function and Altered Functions. New York: Academic press, 1979: pp. 457-75.
7. 7. Angst J. Amrein R, Stabl M. Moclobemide: a paradigm of research in clinical psychopharmacology. Int Clin Psychopharmacol 1995; 11 (suppl 3): 3-7.
8. 8. Hindmarch J, Kerr J. Behavioral toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 1992; 106 (suppl): 49-55.
9. 9. Angst J, Scheidegger P, Stabl M. Efficacy of moclobemide in different patient groups. Clin Neuropharmacol 1993; 16: 16-62.
10. 10. Gattaz WF, Vogel P, Kick H, Kohnen R. Moclobemide versus fluoxetine in the treatment of patients with major depression. Clin Psycopharmacol 1995; 4 (suppl 2): 35-40.
11. 11. Newburn G, Edwards R, Thomas H, Coller J, Fox K, Collins C, Cramer D, Reeves J. A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM III R). J Clin Psychopharmacol 1995; 4 (suppl 2): 10-15.
12. 12. Sheehan DV. Current perspectives in treatment of panic and phobic disorders. Drug Ther 1982; 9: 179-93.
13. 13. Liebowitz MR. Antidepressants in panic disorders. Br J Psychiatry 1989; 5 (suppl 6): 46-52.
14. 14. Versiani M, Nordi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353-60.
15. 15. Williams R, Edwards RA, Newburn GM, Mullen R, Menkes DB, Segkar C. A double blind comparison of moclobemide, fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 1993; 7: 155-8.
16. 16. Fairweather DB, Hindmarch I. The behavioral toxicity of reversible inhibitors of monoamine oxidase. A laboratory and clinical investigation. J Clin Psychopharmacol 1995; 15(suppl 2): 68-75.
17. 17. De Angelis L. Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 354: 379-83.
18. 18. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41: 751-63.
19. 1A agonists. Behav Pharmacol 1994; 5: 42-51.
20. 20. Dawson RG, Tricklebank MD. Use of the elevated plus-maze in search for novel anxiolytic agents. TIPS 1995; 16: 33-6.
21. 21. L' Heureux R, Dennis T, Curet O, Scatton B. Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis. Effects of drugs affecting noradrenergic transmission. J Neurochem 1986; 46: 1794-801.
22. 22. Porsolt RD, Bertin A, Blavet N, Deniel M, Jalfre M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979; 57: 201-10.
23. 23. Fellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 1985; 14: 149-67.
24. 24. Jhonston AL, File SE. Sex differences in animal tests of anxiety. Physiol Behav 1991; 49: 245-50.
25. 25. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 1988: 94: 147-61.
26. 26. Burkard WP, Bonetti EP, Da Prada M, Martin JR, Petar P, Schaffner R, Scherschlicht R, Hefti F, Müller RKM, Wyss PC, Haefely W. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989; 248: 391-9.
27. 27. Miura H, Naoi M, Nakahara D, Ohta T, Nagatsu T. Effects of moclobemide on forced-swimming stress and brain monoamine levels in mice. Pharmacol Biochem Behav 1996; 53: 469-75.
28. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 1989; 169: 1-10.
29. 1A ligands in the elevated X-maze and effects of dorsal raphe lesions. Psychopharmacology 1992; 106: 484-90.
30. 30. Pratt JA. The neuroanatomical basis of anxiety. Pharmacol Ther 1992; 55: 149-81.
31. 31. Redmond DE, Huang YH. Current concepts II. New evidence for the locus coeruleus norepinephrine connection with anxiety. Life Sci 1979; 25: 2149-62.
32. 32. Handley SL, McBlane JW. Serotonin mechanisms in animal models of anxiety. Braz J Med Biol Res 1993; 26: 1-13.
33. 33. Cedarbaum JM, Aghajanian GK. Activation of locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane. Brain Res 1976; 112: 413-19.
34. 34. Charney DS, Heninger GR, Redmond DE Jr. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 1983; 33: 19-29.
35. 35. Davis M, Redmond DE Jr, Baraban JM. Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm. Psychopharmacology 1979; 65: 111-18.
36. 36. File SE, Hyde JRG. A test for anxiety that distinquishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. Pharmacol Biochem Behav 1979; 11: 65-9.
37. 37. Handley SL, Mithani S. Effects of α-adrenoceptor agonists and antagonists in maze exploration model of 'fear'-motivated behavior. Naunyn-Schmiedeberg's Arch Pharmacol 1984; 327: 1-5.
38. 38. Fellow S, Chopin P, File SE. Validation of open:closed arm entries in an elevated plus-maze. A novel test of anxiety in the rat. Pharmacol Biochem Behav 1985; 24: 525-9.
39. 39. Murphy DL, Aulakh CS, Garrick NA, Sunderland T. Monoamin oxiase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987: pp. 545-52.
40. 40. Finberg JPM. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Acta Psychiatr Scand 1995; 91 (suppl): 8-13.
41. 41. Engberg G. A metabolite of buspirone increases loeus coeruleus activity via alpha2-receptor blockade. J Neural Transm 1989; 76: 91-8.
42. 42. Winter JC, Rabin RA. Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther 1992; 263: 682-9.
43. 43. Söderpalm A, Blomquist O, Söderpalm B. The yohimbine-induced anticonflict effect in the rat, part I. Involvement of noradrenergic, serotonergic and endosepinergic (?) mechanisms. J Neural Transm (Gen Sect) 1995; 100: 175-80.